|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||1.4600 - 1.6400|
|52-week range||1.3500 - 7.4000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
VANCOUVER, Washington, August 02, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company, announced today that the director nominations submitted by an activist group led by Paul Rosenbaum and Bruce Patterson (the "Rosenbaum/Patterson Group") were invalid. The Rosenbaum/Patterson Group attempted to nominate five director candidates to take over control of the Company’s six-member Board of Directors (the "Board").
NEW YORK, July 01, 2021--A group of long-time stockholders (the "Nominating Stockholders") of CytoDyn Inc. ("CYDY or the "Company) (OTC: CYDY) today announced that it has sent a notice to CYDY nominating five highly experienced director candidates – Thomas Errico, MD, Bruce Patterson, MD, Paul Rosenbaum, Peter Staats, MD and Melissa Yaeger – to serve on the Company’s Board of Directors.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 17, 2021 to file lead plaintiff applications in securities class action lawsuits against CytoDyn, Inc. (OTC: CYDY), if they purchased the Company’s securities between March 27, 2020 through March 9, 2021, inclusive (the "Class Period"). These actions are pending in the United States District Court for the Western District of Washington.